Evaluating Glioblastoma Treatment Centers in India: What to Assess

Choosing where to treat glioblastoma (GBM) is one of the most important decisions a caregiver or patient will make. When you consider a center in India - whether for surgery, radiation, a second opinion, or full treatment - it can be hard to tell from the outside whether a program is truly equipped or just markets itself well. This guide gives you a concrete framework: seven criteria that matter clinically, plus the questions to ask before you commit.

What Should You Look For When Evaluating a Glioblastoma Treatment Center in India?

A strong GBM program in India has seven core features: a weekly neuro-oncology tumor board, in-house MGMT and IDH molecular testing, fluorescence- and navigation-guided surgery, high-precision radiation (IMRT, stereotactic radiosurgery, or proton), access to Tumor Treating Fields, a neuro-oncologist managing medical treatment, and a dedicated international patient coordinator who handles records, visas, and remote follow-up.

1. Does the Center Have a Dedicated Neuro-Oncology Tumor Board?

A tumor board is a scheduled meeting where neurosurgeons, neuro-oncologists, radiation oncologists, neuropathologists, and radiologists review each case together. For glioblastoma, this is not optional - it shapes every decision from surgical approach to which chemotherapy to use and whether molecular findings change the standard plan.

The National Brain Tumor Society explains that a brain tumor board brings specialists together to review imaging, pathology, and treatment options as a group rather than separately. Programs that meet weekly with a full team of neuro-oncology specialists give patients better care than programs where the neurosurgeon makes decisions alone.

When you contact a center, ask directly: How often does the neuro-oncology tumor board meet? Who sits on the board? Can you confirm that my case will be presented at a board meeting before treatment starts?

2. What Molecular Testing Does the Center Run In-House?

GBM diagnosis today requires more than tissue examination. The World Health Organization's 2021 classification requires molecular markers to assign the correct diagnosis and grade. For GBM specifically, the key tests are MGMT promoter methylation, IDH mutation status, TERT promoter mutation, and EGFR amplification.

MGMT methylation is the most treatment-relevant marker. Research in Neuro-Oncology shows that MGMT methylation is the strongest predictor of how patients respond to temozolomide chemotherapy, and that approximately 40% of IDH-wildtype glioblastomas carry this marker. If a center does not test for MGMT, the clinical team cannot make an informed decision about whether to use or modify standard temozolomide-based chemotherapy.

A review of molecular testing in gliomas on PubMed Central notes that IDH status is also critical because it determines whether a tumor is truly glioblastoma (IDH-wildtype) or a lower-grade tumor that doctors may have misclassified - a distinction that changes both prognosis and treatment strategy significantly.

Ask the center: Which molecular markers do you test for? Does your own pathology lab run these tests, or do you send samples to an external reference lab? How long do results take? Does the tumor board hold its planning meeting until molecular data is back?

Our guide to the glioblastoma second opinion - components, tests, and expert review checklist covers what a complete molecular workup should include and how to verify that nothing has been missed.

3. What Surgical Capabilities Does the Center Offer?

For glioblastoma, maximal safe resection - removing as much tumor as can be safely reached - gives patients better outcomes. The techniques that help achieve this safely are limited to some hospitals, and confirming them specifically matters more than relying on general claims about surgical excellence.

The key surgical technologies to ask about are:

• 5-ALA fluorescence-guided surgery: A drug taken before the operation that makes tumor cells glow pink under blue light, helping the surgeon see and remove tumor tissue that looks identical to normal brain under white light. Our guide to fluorescence-guided surgery for glioma explains how this works and what the evidence shows about extent of resection.
• Intraoperative MRI (iMRI) or neuro-navigation: Real-time imaging or GPS-style navigation that shows the surgeon the tumor's position relative to critical brain structures during the operation. Not all centers have iMRI, but neuro-navigation is more widely available and should still be confirmed.
• Awake craniotomy: For tumors near speech or motor areas, operating while the patient is briefly conscious allows the team to test language and movement in real time, reducing the risk of permanent deficit. Ask whether the center's neurosurgeons are trained in this technique and how many awake procedures they have performed.
• Neuro-intensive care unit (neuro-ICU): Post-operative care for brain tumor patients requires specialist nursing and monitoring. A dedicated neuro-ICU staffed around the clock shows a serious program - and is a question worth asking specifically.

Ask: How many GBM resections does your neurosurgery team perform per year? Do you use 5-ALA routinely? Do you have intraoperative imaging? Who covers the neuro-ICU overnight?

4. What Radiation Technology Does the Center Have?

Standard radiation for glioblastoma is 60 Gy delivered in 30 fractions over six weeks, concurrent with temozolomide chemotherapy. However, the precision with which that radiation is delivered matters. Older linear accelerators deliver broader beams that expose more surrounding brain tissue to dose. Modern techniques spare more of it.

Look for these radiation capabilities:

• IMRT or VMAT: Intensity-modulated radiation therapy and volumetric-modulated arc therapy shape the radiation beam tightly around the tumor volume. These are now standard at serious centers and significantly reduce dose to nearby healthy brain compared to older conformal techniques.
• Stereotactic radiosurgery (SRS): Platforms such as Gamma Knife, CyberKnife, or a LINAC-based SRS system deliver high doses with sub-millimeter accuracy. SRS may be relevant for recurrent GBM or as a focal boost in selected protocols.
• Proton therapy: Protons deposit most of their energy at a precise depth (the Bragg peak), sparing tissue beyond the target. Proton therapy for GBM is not yet standard, but doctors may consider it for specific cases - particularly in younger patients or for re-irradiation. Apollo Proton Cancer Centre in Chennai is the first dedicated proton facility in South Asia and treats adult and pediatric brain tumors.

Ask which radiation platform the center uses for GBM, whether treatment planning uses MRI-CT fusion, and whether a specialized neuro-radiation oncologist oversees GBM cases on the team.

5. Does the Center Offer Tumor Treating Fields?

Tumor Treating Fields (TTFields, branded as Optune) is an FDA-cleared wearable device that delivers low-intensity alternating electric fields to the scalp, disrupting tumor cell division. A PubMed Central article on TTFields describes the phase III EF-14 trial, which showed that adding TTFields to maintenance temozolomide improved median overall survival compared to temozolomide alone in newly diagnosed GBM.

TTFields is available at select major cancer centers in India. Availability varies by institution and city. Ask the specific center whether they have an active Optune program, whether a device can be provided during your stay, and whether the team has experience fitting and monitoring patients on TTFields through all phases including concurrent chemoradiation and maintenance.

Our detailed article on Tumor Treating Fields (Optune) for glioblastoma explains the mechanism, the compliance requirements, and what daily life on the device looks like in practice.

6. How Does the Center Handle International Patients?

Strong clinical capabilities alone won't help if logistics coordination fails. The experience of traveling from many countries for GBM treatment depends heavily on what surrounds the clinical work. Sorting this out in advance is not an administrative detail - it is part of the treatment plan.

The areas to assess are:

• A named international patient coordinator: A specific person, not just a call center, who knows your case, can answer questions about logistics, and is reachable on a consistent channel (email or WhatsApp). If the center cannot give you a name, that is a gap.
• Medical visa support: India's medical visa (MV category) requires a letter from the treating Indian hospital. Ask whether the center provides this as a routine step, how long it takes, and whether dependent visas for accompanying family members are arranged at the same time.
• Remote records review before you travel: The center should review your MRI series and pathology report before offering a treatment plan or asking you to book travel. Ask which clinicians will review the records, whether those are the same clinicians who will treat you, and in what format they prefer to receive imaging - CD, DICOM files, or secure digital upload.
• Language support: Ask whether interpreters are available in your language. Arabic, French, Swahili, and Bengali are relevant for many international communities that travel to India for GBM care.
• Remote follow-up after you leave: The maintenance phase of standard GBM treatment runs for approximately six months. MRI scans and oncology reviews during this period will often happen back in your home country. Ask whether the center has a structured video consultation service for follow-up after you return, and whether they will coordinate with your local oncologist in writing.

7. How to Verify What a Center Claims

Hospital websites and medical tourism facilitators may not show current reality. Equipment listed in a brochure might be under maintenance, recently installed with limited use, or run by a team that mostly handles other tumor types. Here is how to test the claims before you commit.

Ask for written confirmation of current equipment availability. Request a brief written note that the specific technology - 5-ALA, iMRI, proton - is currently operational and available for your admission window. If a center hesitates on this point, that is informative.

Ask about GBM-specific caseload. The American Brain Tumor Association advises patients to ask how many brain tumor patients a center diagnoses and treats per year. A general neurosurgery unit that sees 10 GBM cases a year is structurally different from a dedicated neuro-oncology program that sees 100 or more. Ask how many GBM resections the lead neurosurgeon has performed in the past 12 months.

Ask who performs the molecular testing. Is it the hospital's own NABL-accredited pathology laboratory, or does the sample go to an external reference lab? External labs are not necessarily inferior, but turnaround time matters - and the tumor board should not start treatment planning until molecular data is back.

Get an independent review before you travel. Having pathology and imaging reviewed by an independent expert allows you to compare what that expert recommends against what the Indian center proposes. This is especially useful if you have already received different advice from several doctors. If you are not sure where to start, you can arrange a remote second opinion through Art of Healing Cancer, where the team reviews pathology and MRI before you make a travel decision.

Red Flags to Watch For

Some patterns should give you pause regardless of how polished the marketing looks:

• Any guarantee of a specific survival outcome or cure rate. GBM is a disease where individual outcomes vary widely, and no responsible clinician will promise a fixed result.
• Pressure to travel quickly or pay a deposit before your records have been reviewed by the clinical team.
• No in-house molecular testing - or clinical staff who cannot explain what MGMT methylation testing is when asked directly.
• No tumor board, or a tumor board that meets less than weekly.
• A single contact who functions as both a clinical advisor and the person collecting the treatment deposit. This blurs clinical and commercial roles, which lets commission influence medical recommendations.

When to Talk to Your Doctor

If you are comparing centers in India with options closer to home, bring this list of questions to your current oncologist and ask them to help you interpret the answers. If your current team cannot engage with these questions, that is itself a data point worth noting - it may mean an independent second opinion consultation is overdue.

If you have scans and a pathology report ready and want a structured expert review before you commit to any program, you can upload your records through the Glioblastoma Center patient journey form to request a remote case review.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.